Vivos Therapeutics, Inc. announced its commercial launch of AireO2, a new patient management software technology that will enable healthcare professionals to more effectively diagnose, treat and monitor patients with obstructive sleep apnea and its related conditions. OSA is one of the most prevalent diseases in the world. Approximately 1 billion people globally suffer from OSA, and as many as 80 percent of people who have sleep apnea remain undiagnosed. Left untreated, OSA may increase the risk of comorbidities, such as high blood pressure /hypertension, heart failure, stroke and other debilitating and life-threatening diseases. Developed in collaboration with Lyon Dental, AireO2 contains features that enhance healthcare professionals’ billing services and more, including practice management systems.